169 related articles for article (PubMed ID: 36475694)
1. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Gao S; Song L; Claff T; Woodson M; Sylvester K; Jing L; Weiße RH; Cheng Y; Sträter N; Schäkel L; Gütschow M; Ye B; Yang M; Zhang T; Kang D; Toth K; Tavis J; Tollefson AE; Müller CE; Zhan P; Liu X
J Med Chem; 2022 Dec; 65(24):16902-16917. PubMed ID: 36475694
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.
Gao S; Sylvester K; Song L; Claff T; Jing L; Woodson M; Weiße RH; Cheng Y; Schäkel L; Petry M; Gütschow M; Schiedel AC; Sträter N; Kang D; Xu S; Toth K; Tavis J; Tollefson AE; Müller CE; Liu X; Zhan P
J Med Chem; 2022 Oct; 65(19):13343-13364. PubMed ID: 36107752
[TBL] [Abstract][Full Text] [Related]
3. Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
Khatua K; Alugubelli YR; Yang KS; Vulupala VR; Blankenship LR; Coleman D; Atla S; Chaki SP; Geng ZZ; Ma XR; Xiao J; Chen PH; Cho CD; Sharma S; Vatansever EC; Ma Y; Yu G; Neuman BW; Xu S; Liu WR
Antiviral Res; 2024 May; 225():105874. PubMed ID: 38555023
[TBL] [Abstract][Full Text] [Related]
4. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
5. Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease.
Huang C; Zeng R; Qiao J; Quan B; Luo R; Huang Q; Guo N; Li Y; Long X; Ma R; Xia A; Fang Z; Wang Y; Li Y; Zheng Y; Li L; Lei J; Yang S
Eur J Med Chem; 2023 Nov; 259():115657. PubMed ID: 37517202
[TBL] [Abstract][Full Text] [Related]
6. Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors.
Fink EA; Bardine C; Gahbauer S; Singh I; Detomasi TC; White K; Gu S; Wan X; Chen J; Ary B; Glenn I; O'Connell J; O'Donnell H; Fajtová P; Lyu J; Vigneron S; Young NJ; Kondratov IS; Alisoltani A; Simons LM; Lorenzo-Redondo R; Ozer EA; Hultquist JF; O'Donoghue AJ; Moroz YS; Taunton J; Renslo AR; Irwin JJ; García-Sastre A; Shoichet BK; Craik CS
Protein Sci; 2023 Aug; 32(8):e4712. PubMed ID: 37354015
[TBL] [Abstract][Full Text] [Related]
7. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
Awoonor-Williams E
Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability.
Gao S; Song L; Sylvester K; Mercorelli B; Loregian A; Toth K; Weiße RH; Useini A; Sträter N; Yang M; Ye B; Tollefson AE; Müller CE; Liu X; Zhan P
J Med Chem; 2023 Dec; 66(23):16426-16440. PubMed ID: 37992202
[TBL] [Abstract][Full Text] [Related]
9. Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV-2 main protease.
Wang F; Zeng R; Qiao J; Xia A; Li Y; Li F; Wu Y; Liu Y; Zhao X; Lei J; Yang S
Bioorg Med Chem Lett; 2023 Aug; 92():129407. PubMed ID: 37437852
[TBL] [Abstract][Full Text] [Related]
10. Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors.
Maltarollo VG; da Silva EB; Kronenberger T; Sena Andrade MM; de Lima Marques GV; Cândido Oliveira NJ; Santos LH; Oliveira Rezende Júnior C; Cassiano Martinho AC; Skinner D; Fajtová P; M Fernandes TH; Silveira Dos Santos ED; Rodrigues Gazolla PA; Martins de Souza AP; da Silva ML; Dos Santos FS; Lavorato SN; Oliveira Bretas AC; Carvalho DT; Franco LL; Luedtke S; Giardini MA; Poso A; Dias LC; Podust LM; Alves RJ; McKerrow J; Andrade SF; Teixeira RR; Siqueira-Neto JL; O'Donoghue A; de Oliveira RB; Ferreira RS
Future Med Chem; 2023 Jun; 15(11):959-985. PubMed ID: 37435731
[No Abstract] [Full Text] [Related]
11. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
[TBL] [Abstract][Full Text] [Related]
12. Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 M
Zhang K; Wang T; Li M; Liu M; Tang H; Wang L; Ye K; Yang J; Jiang S; Xiao Y; Xie Y; Lu M; Zhang X
Eur J Med Chem; 2023 Sep; 257():115487. PubMed ID: 37257212
[TBL] [Abstract][Full Text] [Related]
13. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.
Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI
Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346
[TBL] [Abstract][Full Text] [Related]
14. Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CL
Wang F; Liu D; Gao D; Yuan J; Zhao J; Yuan S; Cen Y; Lin GQ; Zhao J; Tian P
Int J Biol Macromol; 2024 Apr; 264(Pt 1):130377. PubMed ID: 38395279
[TBL] [Abstract][Full Text] [Related]
15. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M
Hicks EG; Kandel SE; Lampe JN
Bioorg Med Chem Lett; 2022 Jun; 66():128732. PubMed ID: 35427739
[TBL] [Abstract][Full Text] [Related]
16. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
Eur J Med Chem; 2022 Oct; 240():114570. PubMed ID: 35779291
[TBL] [Abstract][Full Text] [Related]
17. Easy access to α-ketoamides as SARS-CoV-2 and MERS M
Pelliccia S; Cerchia C; Esposito F; Cannalire R; Corona A; Costanzi E; Kuzikov M; Gribbon P; Zaliani A; Brindisi M; Storici P; Tramontano E; Summa V
Eur J Med Chem; 2022 Dec; 244():114853. PubMed ID: 36332546
[TBL] [Abstract][Full Text] [Related]
18. The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.
Pang X; Xu W; Liu Y; Li H; Chen L
Eur J Med Chem; 2023 Sep; 257():115491. PubMed ID: 37244162
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of SARS-CoV-2 main protease (M
Jiang H; Zou X; Zhou X; Zhang J; Li J
Biochem Biophys Res Commun; 2024 Jan; 692():149352. PubMed ID: 38056159
[TBL] [Abstract][Full Text] [Related]
20. Diphenyl Diselenide and SARS-CoV-2:
Omage FB; Madabeni A; Tucci AR; Nogara PA; Bortoli M; Rosa ADS; Neuza Dos Santos Ferreira V; Teixeira Rocha JB; Miranda MD; Orian L
J Chem Inf Model; 2023 Apr; 63(7):2226-2239. PubMed ID: 36952618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
